These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31394493)

  • 1. Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study.
    Charoensareerat T; Chaijamorn W; Boonpeng A; Srisawat N; Pummangura C; Pattharachayakul S
    J Crit Care; 2019 Dec; 54():77-82. PubMed ID: 31394493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
    Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
    Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
    Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
    J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Chaijamorn W; Charoensareerat T; Charntrakarn P; Khamkampud O; Rattanaponpasert N; Srisawat N; Pattharachayakul S
    J Crit Care; 2021 Jun; 63():154-160. PubMed ID: 33012583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.
    Mei Q; Ye Y; Zhu YL; Cheng J; Yang HF; Liu YY; Li HR; Li JB
    Int J Antimicrob Agents; 2015 Jun; 45(6):652-6. PubMed ID: 25813394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.
    Moffett BS; Morris J; Munoz F; Arikan AA
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1089-1097. PubMed ID: 30937470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
    Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin: we can't get there from here.
    Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
    Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
    Villanueva RD; Talledo O; Neely S; White B; Celii A; Cross A; Kennedy R
    J Trauma Acute Care Surg; 2019 Nov; 87(5):1164-1171. PubMed ID: 31464871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing vancomycin in the super obese: less is more.
    Crass RL; Dunn R; Hong J; Krop LC; Pai MP
    J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
    Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
    Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.